Novartis biosimilar cancer drug hits U.S. regulatory bump

ZURICH, May 3 (Reuters) - Novartis AG said its biosimilar version of rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis had not won regulatory approval from the U.S. Food and Drug Administration (FDA).